Acute symptomatic seizures and epilepsy after mechanical thrombectomy

Eriksson H1,2, Löwhagen Hendén P2,3, Rentzos A2,4, Pujol-Calderón F5, Karlsson JE1,2, Höglund K5,6, Blennow K5,6, Zetterberg H5,6,7,8, Rosengren L1,2, and Zelano J1,2*

1 Department of Clinical Neuroscience, Sahlgrenska Academy, University of Gothenburg

2 Sahlgrenska University Hospital, Sweden. Blå stråket 7, 413 46 Sweden.

3 Department of Anesthesiology and Intensive Care, Sahlgrenska Academy, University of Gothenburg

4 Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg

5 Department of Psychiatry & Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

6 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

7 UK Dementia Research Institute at UCL, London, United Kingdom

8 Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom

*Corresponding author: johan.zelano@neuro.gu.se

Manuscript type: Special issue Original article
Declaration of interest: HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Biogen and Alzecure, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (all outside submitted work). KB has served as a consultant or at advisory boards for Alector, Alzheon, CogRx, Biogen, Lilly, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. JZ reports consultancy fee from the Swedish Medical Products agency, and has been investigator/sub-investigator without personal compensation in clinical trials at Sahlgrenska university hospital sponsored by Bial, SK Life science, and GW Pharma.
Abstract (245 words)

**Purpose:** To assess the incidence of acute symptomatic seizures and post-stroke epilepsy (PSE) in a well-characterized cohort of patients treated with mechanical thrombectomy. In addition, we aimed to describe the dynamics of blood markers of brain injury in patients that developed PSE.

**Methods:** Participants of the prospective AnStroke Trial of anesthesia method during mechanical thrombectomy were included and acute symptomatic seizures and PSE ascertained by medical records review. Blood markers NFL, tau, GFAP, S100B, and NSE were assessed.

**Results:** A total of 90 patients with acute anterior ischemic stroke were included. Median NIHSS at admission to hospital was 18 (IQR 15-22). Recanalization was achieved in 90%. No patients had epilepsy prior to the ischemic stroke. Four patients (4.4%) had acute symptomatic seizures and four patients (4.4%) developed PSE during the follow-up time (to death or last medical records review) of 0 - 4.5 years (median follow-up 1070 days IQR 777-1306), resulting in a two-year estimated PSE risk of 5.3% (95%CI: 0.2-10.4%). Blood markers of brain injury (NFL, tau, GFAP, S100B, and NSE) were generally above the cohort median in patients that developed PSE.

**Conclusions:** The incidence of PSE after mechanical thrombectomy was low in our cohort. All blood biomarkers displayed interesting sensitivity and specificity. However, the number of PSE cases was small and more studies are needed on risk factors for PSE after mechanical thrombectomy. The potential of blood markers of brain injury markers to contribute to assessment of PSE risk should be explored further.

Keywords: epilepsy, stroke, rehabilitation
1. Introduction

Emergency revascularization is the most important intervention in acute stroke care, with endovascular mechanical thrombectomy (hereinafter thrombectomy) being superior to systemic intravenous thrombolysis for large vessel occlusion [1, 2]. Since stroke severity and cortical involvement – a hallmark feature of embolic stroke - are risk factors for post-stroke epilepsy (PSE) [3-5], candidates for thrombectomy could, at least before successful revascularization, also be at a high risk of subsequent PSE.

There is more information on the occurrence of seizures after revascularization for patients that have received thrombolysis than for patients that have undergone thrombectomy. Reported rates of acute symptomatic seizures (seizures within one week of stroke) in thrombolysis-treated patients vary from approximately 1% to 15% [6-9]. In three relatively recent studies of thrombolysis-treated cohorts, PSE (seizures occurring >1 week after stroke) was reported in 5.8%-16.7% [6, 10, 11]. After thrombectomy, acute symptomatic seizures have been described in 2.4 % [12]. In a large multicenter study of patients receiving different revascularization treatments, PSE occurred in 12.9 % of patients receiving only intra-arterial therapy (thrombectomy or intra-arterial thrombolysis) and treatment was associated with an increased risk of PSE, also with adjustments for stroke severity assessed by mRS [10].

With an increasing number of patients undergoing thrombectomy, more information on the risk of subsequent PSE is important. Ideally, biomarkers for patients at risk should also be identified. We investigated the incidence of acute symptomatic seizures and PSE in participants in the randomized trial AnStroke, which compared sedation vs. general anesthesia in patients undergoing thrombectomy without any demonstrable difference between the groups [13]. During the trial, blood samples were collected for analyses of five blood markers reflecting brain injury in acute stroke [14-17]; we explored their potential as biomarkers for high PSE risk.
2. Material and methods

2.1 Study cohort

The AnStroke Trial included 90 patients aged 18 or older with acute anterior circulation stroke suitable for thrombectomy. The trial evaluated differences in stroke outcome depending on whether the patient had sedation or general anesthesia during thrombectomy, and no such difference was detected [13]. Participants were recruited prospectively from Sahlgrenska University Hospital between 2013 and 2016. The inclusion criteria were NIHSS score > 10 for right-sided occlusion or > 14 for left-sided occlusion. Treatment was initiated within 8 hours after first showing of symptoms and patients were not included if mRS (modified Rankin scale) score > 4 or if neurological recovery or recanalization occurred before or during angiography. Patients were excluded if there were any contraindications to thrombectomy. Infarction volume estimation was made by Computed Tomography (CT) at day 1 in 88 (98 %) of patients, and Magnetic Resonance Imaging (MRI) was performed in 77 patients (86 %) at day 3. Neuroimaging was assessed by several neuroradiologists. In addition to volume measures and anatomical descriptions, lesions were classified according to the Alberta stroke program early CT score (ASPECTS).

2.2 Blood sampling and biochemical analyses.

Blood samples were drawn longitudinally on arrival, at 2h, 24h, 48 h, 72 h, and at three months or later following thrombectomy. Samples were stored at – 80 C after aliquotation. Tau and GFAp concentrations were measured using commercially available tau or GFAp kit Single molecule array (Simoa) 2.0 assays, as described by the manufacturer (Quanterix, Lexington, MA). NFL concentrations were measured using NFL ELISA kit from UmanDiagnostics (NF-light® ELISA kit, UmanDiagnostics AB) and moved to a Simoa assay, as previously described [18]. Concentrations of NSE and S100B were determined using
immunoassays with electrochemiluminescence detection on the Elecsys platform (Roche Diagnostics, Penzberg, Germany).

2.3 Ascertainment of seizures and PSE

Medical records were reviewed and information on seizures was collected into a pre-defined case report form during the spring of 2018. The electronic medical records system in the region covers all hospitals with emergency and neurology departments. Seizures that occurred within seven days after stroke were defined as acute symptomatic seizures and unprovoked seizures occurring more than seven days after stroke were defined as PSE, in agreement with the current ILAE clinical definitions of acute symptomatic seizures and epilepsy [19, 20]. The follow-up time (to death or last medical records review) was 0 - 4.5 years (median follow-up 1070 days IQR 777-1306).

2.4 Statistical analysis

Data were analyzed using IBM SPSS Statistics for Macintosh, version 25.0. Continuous characteristics such as NIHSS score, time, and volumes, were calculated as median (IQR). Categorical values were presented as counts (proportions). Comparison between patients who developed epilepsy versus patients with acute symptomatic seizures was presented as median and compared using Independent Sample T-test. Statistical significance was defined as 2-sided p < 0.05. For Cox and Kaplan-Meier analysis, time was calculated from stroke to PSE with censoring at death or 31/05/2018 (last date of medical records review). Cumulative risks were estimated with Kaplan-Meier survival tables and 95%CI calculated as 1.96 x standard error. Receiver Operating Characteristics (ROC) curves for blood biomarkers were created to evaluate their capacity to discriminate PSE patients from non-PSE patients (patients with acute symptomatic seizures were excluded from this analysis). The cutoff value for each
putative biomarker was first assessed visually, and then more precisely calculated by Youden J index. Sensitivity and specificity were calculated.

2.5 Ethical approval

The regional board of ethics in Gothenburg approved the study (approval no EPN 013-13). Patients or their relatives provided written informed consent.
3. Results

3.1 Study population

Ninety patients with acute ischemic stroke that participated in AnStroke between 2013 and 2016 were included. Baseline characteristics are shown in Table 1. No patients had epilepsy prior to their stroke. One patient had a previous history of an acute symptomatic seizure provoked by alcohol.

3.2 Seizures

Four patients (4.4%) had acute symptomatic seizures, none of these patients developed subsequent PSE. All acute symptomatic seizures occurred within the first three days with a median latency of 1.5 (IQR 0.5-2.5) days. Four (4.4%) patients developed PSE (Fig. 1). The median latency until PSE was 211 (IQR 33-495) days. The Kaplan-Meier estimated risk of PSE was 3.9% (95%CI: 0.0-8.2%) at one year and 5.3% (95%CI: 0.2-10.4%) at two years.

3.3 Clinical characteristics and the risk of PSE

Clinical details on each PSE patient are shown in Table 2. All patients with PSE had successful recanalization. Out of the four patients that developed PSE, all had NIHSS scores at discharge above the median of the study cohort. Two PSE patients had substantial reductions in NIHSS scores after thrombectomy and their infarction volumes on day three were below the cohort median. One patient that later developed PSE had an early stroke recurrence. Patients with acute symptomatic seizures and PSE were not significantly different regarding median age (78 vs 77, p=0.85), NIHSS score on admission (19 vs 22, p=0.5), or NIHSS after three days (12 vs 9, p=0.42), or regarding stroke volumes (5 vs 59, p=0.38).

No baseline characteristic was significantly associated with an increased HR of PSE in univariate Cox regression (p >0.05); age: HR 1.04 (95%CI: 0.95-1.13), NIHSS at
baseline: HR 1.17 (95%CI: 0.92-1.5), time to recanalization: HR 1.00 (95%CI 0.99-1.02),
NIHSS at discharge: HR 1.04 (95%CI: 0.94-1.15), infarction volume day 1: HR 1.01 (95%CI: 1.00-1.02), or infarction volume day 3: HR 1.01 (95%CI: 1.00-1.02).

3.4 Anesthesiologic agents used during thrombectomy
Regarding anesthesiologic agents during thrombectomy, two patients who developed acute symptomatic seizures received general anesthesia induced with propofol and maintained with remifentanil infusion and sevoflurane. Two patients who developed acute symptomatic seizures received conscious sedation with lower dosages of remifentanil infusion. Three patients who developed PSE received conscious sedation and one received general anesthesia.

3.5 Blood biomarkers
All patients that developed PSE had increased levels of blood markers at some point in time (Fig. 2). The concentrations of blood markers in PSE patients were generally above the cohort median. The capacity of brain blood markers to identify PSE patients was explored by ROC analysis. At 48 hours, all four patients who developed epilepsy had a tau concentration >14,045 pg/mL, the optimal cutoff resulting in 100% sensitivity and 73% specificity. The remaining blood markers had optimal cutoff values at three months or later (at the later time points, blood was only available from two patients who subsequently developed PSE). With a sensitivity of 100%, the best specificity for NFL, GFAP, S100B, or NSE was 77% - 93%. Although specificity was high, the number of events was small and no further statistical analysis was performed.
4. Discussion

We describe the incidence of acute symptomatic seizures and PSE in a well-characterized cohort of patients following thrombectomy. Our main finding is that only 4/90 patients (4.4%) developed PSE. The survival-adjusted risk of PSE at two years was 5.3% in our cohort, which is not very different from general stroke cohorts [4]. The literature on risk of PSE after mechanical thrombectomy is currently scarce. The incidence in our cohort is slightly lower than that recently reported in another study that followed patients up to two years, in which 17/205 (8.3%) developed PSE after intra-arterial thrombolysis or thrombectomy, with or without previous intravenous thrombolysis [10]. Importantly, the authors did not specify which patients underwent mechanical thrombectomy, which limits comparability. The PSE rates reported in that study and ours do not exceed that of some cohorts treated with only intravenous thrombolysis, but there are probably substantial differences between thrombolysis-treated patients in general and patients selected for thrombectomy [6, 11].

In our study, 4/90 patients (4.4%) developed acute symptomatic seizures. This is similar to previously reported rates for patients treated with intravenous thrombolytics without thrombectomy [7, 8], but reports range from 1% to 15% [6, 9]. So far, described risks of acute symptomatic seizures or PSE after thrombectomy are relatively low – given that patients selected for therapy are often at risk of very large lesions. There are currently conflicting results regarding whether reperfusion therapies per se are associated with an increased risk of PSE [6, 10]. Publication of data from more cohorts should resolve this issue in the future. Meta-analyses of several cohorts could also focus on risk factors for PSE, which could facilitate recognition and early diagnosis. We could not identify any clinical or radiological factors significantly associated with an increased risk of PSE. In stroke patients in general, regardless of treatment, most studies have found stroke severity to be a risk factor for PSE [3, 4, 21], but we did not see any significant association between baseline NIHSS, or NIHSS at discharge, and subsequent PSE. Stroke severity, assessed as baseline NIHSS and
mRS at follow-up, was also not significantly associated with a higher risk of PSE after revascularization treatment in the cohort described by Naylor [10]. Two studies have failed to demonstrate associations between outcome measures and PSE which suggests that other factors than just lesion size may have an impact on PSE risk after thrombectomy; candidate mechanisms include the degree of cortical involvement, microhaemorrhages, inflammatory response, genetic vulnerability, or blood-brain barrier disruption. There was now obvious association between particular anesthesiologic agents during thrombectomy and subsequent seizures. All anesthetics may dose-dependently induce seizures, barbiturates in particular have been associated with excitatory effects [22], but the material in our study is to small to be very informative in this matter.

To our knowledge, we also publish the first description of brain injury blood markers of patients that developed PSE. Brain injury blood markers can potentially reflect lesion characteristics not demonstrable on neuroimaging, which may improve understanding of PSE epileptogenesis. Most markers reach a maximum value after a few days [14, 23, 24], but NFL can continue to increase for weeks [25]. Analysis of the markers in relation to stroke outcome in the AnStroke cohort is in progress (Pujol-Calderón et al. in preparation). Within the cohort, several blood markers demonstrated good specificity and sensitivity for subsequent PSE. Interestingly, some markers had their optimal discriminative ability months after stroke, indicating that temporal factors like an extended response to injury may be of importance. Although the number of patients that developed PSE was too low for meaningful statistical analysis, the observations merit further study. Some blood markers alone or in combination could be of value in estimating PSE risk. More studies on the dynamics of markers may provide neurobiological insight into epileptogenesis and if a particular “blood marker profile” is associated with high PSE risk.
There are limitations to our study. Ascertainment of epilepsy should be robust, since all hospitals with neurology service in the region share the same electronic medical records system. Generalizability is more questionable. Since the patients participated in a randomized trial of anesthesia form, they were considered suitable for both sedation and general anesthesia. This could mean selection of a healthier cohort than thrombectomy patients in general. The vital parameters of participants were very closely monitored peri-procedurally and systolic blood pressure before recanalization specifically targeted to 140-180 mmHg [13]. The rate of recanalization was also high. Whether conditions during thrombectomy influence PSE risk is an interesting topic for future studies, especially since lesion size does not seem to be the sole determinant of PSE risk.

In summary, we report a relatively low risk of PSE following thrombectomy in the AnStroke trial. The knowledge on risks of PSE after revascularization is limited and more studies are needed. Register-based studies in countries with comprehensive registers or regions with large insurance databases could provide further insight. There is also a need for studies on the impact of potentially modifiable risk factors related to thrombectomy, such as intra-arterial blood pressure or cortical penumbra/lesion. All blood biomarkers displayed interesting sensitivity and specificity. These findings suggest that tau could be measured in acute settings and NFL, GFAP, S100B, and NSE later for evaluation of risk of PSE. Blood markers of brain injury should be studied further as putative biomarkers for predicting PSE.

**Acknowledgements**

Mattias Molin, Statistiska konsultgruppen, Gothenburg, provided statistical advice.
Funding

Swedish Society of Medicine, Swedish Society for Medical Research, Jeansssons foundation, Magnus Bergvall foundation, Felix Neubergh foundation, Region Västra Götaland. HZ is a Wallenberg Academy Fellow supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712) and Swedish State Support for Clinical Research (#ALFGBG-720931). KB holds the Torsten Söderberg Professorship in Medicine at the Royal Swedish Academy of Sciences, and is supported by the Swedish Research Council (#2017-00915), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), and a grant (#ALFGBG-715986) from the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement.
References


Figures and tables

Table 1

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>n = 90</td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>41</td>
<td>(46)</td>
</tr>
<tr>
<td>Males</td>
<td>49</td>
<td>(54)</td>
</tr>
<tr>
<td>Age, yrs median (IQR)</td>
<td>72 (65-80)</td>
<td></td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>14</td>
<td>(16)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>16</td>
<td>(18)</td>
</tr>
<tr>
<td>Smoking</td>
<td>12</td>
<td>(13)</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>36</td>
<td>(40)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>49</td>
<td>(54)</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>12</td>
<td>(13)</td>
</tr>
<tr>
<td>Clinical characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre mRS = 0</td>
<td>85</td>
<td>(94)</td>
</tr>
<tr>
<td>NIHSS baseline median (IQR)</td>
<td>18 (15-22)</td>
<td></td>
</tr>
<tr>
<td>Thrombolysis</td>
<td>69</td>
<td>(77)</td>
</tr>
<tr>
<td>Time from arrival (mins) to recanalization median (IQR)</td>
<td>93 (65-142)</td>
<td></td>
</tr>
<tr>
<td>Successful recanalization</td>
<td>81</td>
<td>(90)</td>
</tr>
<tr>
<td>NIHSS at 24 hours median (IQR)</td>
<td>8 (3-15)</td>
<td></td>
</tr>
<tr>
<td>NIHSS at day 3 median (IQR)</td>
<td>4 (1-13)</td>
<td></td>
</tr>
<tr>
<td>NIHSS at discharge median (IQR)</td>
<td>2 (0-10)</td>
<td></td>
</tr>
<tr>
<td>Radiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infarction volume (ml) day 1 median (IQR)</td>
<td>21 (4-60)</td>
<td></td>
</tr>
<tr>
<td>Infarction volume (ml) day 3 median (IQR)</td>
<td>20 (10-83)</td>
<td></td>
</tr>
<tr>
<td>Acute symptomatic seizure</td>
<td>4</td>
<td>(4)</td>
</tr>
</tbody>
</table>

Baseline demographics and stroke risk factors. Functional level prior stroke is given in mRS score, modified Rankin scale. Successful recanalization means a Modified Treatment In Cerebral Ischemia score (mTICI), of 2b or 3. n (%). NIHSS: National Institutes of Health Stroke Scale.
### Table 2 Clinical characteristics of PSE patients

<table>
<thead>
<tr>
<th>ID</th>
<th>Age</th>
<th>Sex</th>
<th>IVT</th>
<th>Anesthesia method</th>
<th>Infarction volume baseline CT (ml)</th>
<th>Infarction volume, CT day 1 (ml)</th>
<th>Infarction volume, MRI day 3 (ml)</th>
<th>NIHSS at admission</th>
<th>NIHSS at discharge</th>
<th>Cortical lesion MRI day 3</th>
<th>ASPECT S score</th>
<th>Involvement of basal ganglia</th>
<th>Semiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>83</td>
<td>F</td>
<td>Yes</td>
<td>Conscious sedation</td>
<td>1</td>
<td>3</td>
<td>5</td>
<td>16</td>
<td>5</td>
<td>Yes (mostly parietal and temporal)</td>
<td>6 (MRI day 3)</td>
<td>Yes</td>
<td>FIAS</td>
</tr>
<tr>
<td>2</td>
<td>83</td>
<td>F</td>
<td>No</td>
<td>Conscious sedation</td>
<td>37.5</td>
<td>90</td>
<td>100</td>
<td>-</td>
<td>23</td>
<td>Yes (frontal and temporal lobe)</td>
<td>1</td>
<td>Yes</td>
<td>FIAS</td>
</tr>
<tr>
<td>3</td>
<td>70</td>
<td>M</td>
<td>No</td>
<td>General anesthesia</td>
<td>100</td>
<td>230</td>
<td>300</td>
<td>-</td>
<td>23</td>
<td>Yes (frontal, parietal, temporal lobe)</td>
<td>0</td>
<td>Yes</td>
<td>FAS</td>
</tr>
<tr>
<td>4</td>
<td>70</td>
<td>M</td>
<td>Yes</td>
<td>General anesthesia</td>
<td>0</td>
<td>45</td>
<td>17</td>
<td>-</td>
<td>21</td>
<td>Yes (insular and temporal)</td>
<td>6</td>
<td>No</td>
<td>FAS</td>
</tr>
</tbody>
</table>

Fig. 1 Kaplan-Meier curve of PSE. Risk of epilepsy = 1 minus epilepsy-free survival. At risk = the number of remaining cases.
Fig. 2 A – E Concentrations of biomarkers in PSE patients
Concentrations for tau (A), NFL (B), GFAP (C), S-100b (D), NSE (E) in patients that developed PSE.